| Description | Vixtimotamab (AMV-564; TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively engages human CD33 and CD3 antigens. It is utilized in research on acute myeloid leukemia (AML) [1]. |
| In vitro | Vixtimotamab（TandAb T564；24小时）可诱导CD25和CD69表达，其EC50值分别为1 pM和2 pM[1]。Vixtimotamab（TandAb T564；4天）能促进PBMCs中T细胞的增殖，其EC50为3 pM[1]。Vixtimotamab（TandAb T564；25 pM，48小时）对HL-60和KG-1a细胞展现出细胞毒作用[1]。 |
| In vivo | Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5天) 在预防性HL-60移植的NOD/scid小鼠模型中表现出剂量依赖性的肿瘤生长延迟效应[1]。同一化合物（50 μg/mouse/d, i.v.; 7天）在已建立的HL-60移植NOD/scid小鼠模型中有效抑制肿瘤生长[1]。 |
| Synonyms | TandAb T564, AMV-564 |
| molecular weight | N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |